Join to access to all OVN content. Join for Free
Leadership Lab: How To Spot When Employees Are About To Walk Away
careers

Leadership Lab: How To Spot When Employees Are About To Walk Away


Share This Article


Summary

Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that helps leaders identify when their team members are thinking about heading for the exit—and how to address it.

Welcome to Leadership Lab, a column dedicated to biopharma executives aiming to enhance their leadership skills and advance their careers. Every other month, Michael Pietrack, the practice lead for Kaye/Bassman’s pharma and biotech recruiting team and host of “The Pharmaverse Podcast,” shares a valuable leadership insight. 

In biopharma, people are every bit as valuable as the science. You can have the most promising pipeline in the industry, but without the right leaders, scientists and field professionals to bring it to life, progress stalls. That’s why turnover hurts so much. Losing a key person at the wrong moment can disrupt the delicate balance of a high-performing team. This article shares how you can spot the signs early enough to do something about it.

Identifying the Signs: The CLAMPS Framework

Most employees don’t leave on a whim. They wrestle with the decision for months. If leaders are paying attention, they can usually spot the signs of restlessness before a resignation letter hits their desk. A helpful way to frame those signals is through the CLAMPS framework. The acronym stands for challenge, location, advancement, money, people and security. Each of these six factors plays into a professional’s decision to stay or go, and each can be proactively addressed by leaders who are serious about retention.

1. Challenge: employees need to be engaged but not overwhelmed

High performe

rs thrive on being stretched, yet they’re also the ones who can do their jobs on autopilot once things get too predictable. When someone who used to light up with enthusiasm suddenly disengages, it may not be laziness. More often, it’s a sign that they’re bored. In biopharma, this can be particularl
Click for Source

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
3 Things I wish I knew about being a MSL
Partner Avatar MSL Talk: Tom Caravela, Mitchell D’Rozario

3 Things I wish I knew about being a MSL

Article
The Great Resignation is Now The Great Hesitation
Partner Avatar Michael Pietrack

The Great Resignation is Now The Great Hesitation

Article
How to Know When to Make a Job Change
Partner Avatar Michael Pietrack

How to Know When to Make a Job Change

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Explore OVN